General Information of Drug (ID: DM8L9D4)

Drug Name
Bestatin Drug Info
Synonyms
Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Cross-matching ID
PubChem CID
72172
CAS Number
CAS 58970-76-6
TTD Drug ID
DM8L9D4
VARIDT Drug ID
DR00275

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LYS006 DMI17QR Ulcerative colitis DD71 Phase 2 [5]
Acebilustat DM19UTO Chronic blistering skin disorder ME63.3 Phase 1 [6]
DG051 DM3I0GS Myocardial infarction BA41-BA43 Discontinued in Phase 2 [7]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [8]
JNJ-10392980 DMZH0K8 Discovery agent N.A. Investigative [9]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [10]
2-(4-phenoxyphenoxy)ethanamine DM7TBUJ Discovery agent N.A. Investigative [11]
3-(Benzyloxy)Pyridin-2-Amine DM35VEI Discovery agent N.A. Investigative [8]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO Discovery agent N.A. Investigative [12]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole DMMYJ3R Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 1 (SLC15A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [13]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [14]
Ampicillin DMHWE7P Acute epiglottitis Approved [15]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [16]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [17]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [18]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [19]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [14]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [16]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 2 (SLC15A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [13]
Ampicillin DMHWE7P Acute epiglottitis Approved [20]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [21]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [22]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [23]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [20]
Valaciclovir DMHKS94 Genital herpes 1A94 Approved [24]
Cefaclor DMJXDGC Bacterial infection 1A00-1C4Z Approved [13]
Aminolevulinic acid hci DMS4BLQ Acne vulgaris ED80 Approved [25]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [26]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene A-4 hydrolase (LTA4H) TTXZEAJ LKHA4_HUMAN Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [3]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5151).
2 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
3 Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol. 2008 Jun;294(6):F1422-32.
4 Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol. 1993 Aug;265(2 Pt 1):G289-94.
5 Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
10 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11 Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
12 Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
13 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
14 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
15 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
16 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
17 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
18 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
19 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
20 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
21 Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
22 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
23 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
24 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
25 PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
26 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.